These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38621133)

  • 1. Lecanemab blocks the effects of the Aβ/fibrinogen complex on blood clots and synapse toxicity in organotypic culture.
    Singh PK; Simões-Pires EN; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2314450121. PubMed ID: 38621133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lecanemab Blocks the Effects of the Aβ/Fibrinogen Complex on Blood Clots and Synapse Toxicity in Organotypic Culture.
    Singh PK; Pires ENS; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
    bioRxiv; 2024 Jan; ():. PubMed ID: 38293058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
    Johannesson M; Söderberg L; Zachrisson O; Fritz N; Kylefjord H; Gkanatsiou E; Button E; Svensson AS; Rachalski A; Nygren P; Osswald G; Lannfelt L; Möller C
    Mol Cell Neurosci; 2024 Sep; 130():103949. PubMed ID: 38906341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease.
    Chen ZL; Singh PK; Calvano M; Norris EH; Strickland S
    Proc Natl Acad Sci U S A; 2023 Sep; 120(36):e2309389120. PubMed ID: 37639602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization.
    Ahn HJ; Zamolodchikov D; Cortes-Canteli M; Norris EH; Glickman JF; Strickland S
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21812-7. PubMed ID: 21098282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β-amyloid fibrinogen interaction.
    Chung YC; Kruyer A; Yao Y; Feierman E; Richards A; Strickland S; Norris EH
    J Thromb Haemost; 2016 Jul; 14(7):1442-52. PubMed ID: 27090576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.
    Cortes-Canteli M; Paul J; Norris EH; Bronstein R; Ahn HJ; Zamolodchikov D; Bhuvanendran S; Fenz KM; Strickland S
    Neuron; 2010 Jun; 66(5):695-709. PubMed ID: 20547128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice.
    Ahn HJ; Glickman JF; Poon KL; Zamolodchikov D; Jno-Charles OC; Norris EH; Strickland S
    J Exp Med; 2014 Jun; 211(6):1049-62. PubMed ID: 24821909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
    Lannfelt L
    Ups J Med Sci; 2023; 128():. PubMed ID: 38084203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
    Vitek GE; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen and altered hemostasis in Alzheimer's disease.
    Cortes-Canteli M; Zamolodchikov D; Ahn HJ; Strickland S; Norris EH
    J Alzheimers Dis; 2012; 32(3):599-608. PubMed ID: 22869464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.
    Singh PK; Kawasaki M; Berk-Rauch HE; Nishida G; Yamasaki T; Foley MA; Norris EH; Strickland S; Aso K; Ahn HJ
    Biochemistry; 2018 Feb; 57(8):1399-1409. PubMed ID: 29394041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen.
    Cajamarca SA; Norris EH; van der Weerd L; Strickland S; Ahn HJ
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14482-14492. PubMed ID: 32518112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
    McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.